BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29369808)

  • 21. Anti-CENP-B and anti-TOPO-1-containing sera from systemic sclerosis-related diseases with Raynaud's phenomenon induce vascular endothelial cell senescence not via classical p53-p21 pathway.
    Shen CY; Li KJ; Lai PH; Yu CL; Hsieh SC
    Clin Rheumatol; 2018 Mar; 37(3):749-756. PubMed ID: 28940121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.
    Perosa F; Favoino E; Favia IE; Vettori S; Prete M; Corrado A; Cantatore FP; Valentini G
    Medicine (Baltimore); 2016 Jun; 95(25):e3931. PubMed ID: 27336883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.
    Vázquez-Abad D; Grodzicky T; Senécal JL
    Clin Immunol; 1999 Feb; 90(2):182-9. PubMed ID: 10080829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoantibodies to a novel Rpp38 (Th/To) derived B-cell epitope are specific for systemic sclerosis and associate with a distinct clinical phenotype.
    Koenig M; Bentow C; Satoh M; Fritzler MJ; Senécal JL; Mahler M
    Rheumatology (Oxford); 2019 Oct; 58(10):1784-1793. PubMed ID: 31323671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis.
    Favoino E; Digiglio L; Cuomo G; Favia IE; Racanelli V; Valentini G; Perosa F
    PLoS One; 2013; 8(4):e61453. PubMed ID: 23613856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fine-specificity of the anti-CENP-A B-cell autoimmune response.
    Mahler M; Mierau R; Blüthner M
    J Mol Med (Berl); 2000; 78(8):460-7. PubMed ID: 11097115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epitope Specificity Determines Pathogenicity and Detectability of Anti-Platelet-Derived Growth Factor Receptor α Autoantibodies in Systemic Sclerosis.
    Moroncini G; Grieco A; Nacci G; Paolini C; Tonnini C; Pozniak KN; Cuccioloni M; Mozzicafreddo M; Svegliati S; Angeletti M; Kazlauskas A; Avvedimento EV; Funaro A; Gabrielli A
    Arthritis Rheumatol; 2015 Jul; 67(7):1891-903. PubMed ID: 25808833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles.
    Tan FK; Arnett FC; Reveille JD; Ahn C; Antohi S; Sasaki T; Nishioka K; Bona CA
    Arthritis Rheum; 2000 Nov; 43(11):2464-71. PubMed ID: 11083269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis.
    Pauling JD; Salazar G; Lu H; Betteridge ZE; Assassi S; Mayes MD; McHugh NJ
    Rheumatology (Oxford); 2018 Apr; 57(4):712-717. PubMed ID: 29294089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies.
    Akbarali Y; Matousek-Ronck J; Hunt L; Staudt L; Reichlin M; Guthridge JM; James JA
    J Autoimmun; 2006 Dec; 27(4):272-80. PubMed ID: 17210244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects.
    Wodkowski M; Hudson M; Proudman S; Walker J; Stevens W; Nikpour M; Assassi S; Mayes MD; Tatibouet S; Wang M; ; ; ; Baron M; Fritzler MJ
    Autoimmunity; 2015; 48(8):542-51. PubMed ID: 26334795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis.
    Hudson M; Pope J; Mahler M; Tatibouet S; Steele R; Baron M; ; Fritzler MJ
    Arthritis Res Ther; 2012 Mar; 14(2):R50. PubMed ID: 22394602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticentromere antibody-positive primary Sjögren's syndrome: Epitope analysis of a subset of anticentromere antibody-positive patients.
    Tanaka N; Muro Y; Suzuki Y; Nishiyama S; Takada K; Sekiguchi M; Hashimoto N; Ohmura K; Shimoyama K; Saito I; Kawano M; Akiyama M
    Mod Rheumatol; 2017 Jan; 27(1):115-121. PubMed ID: 27161330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis.
    Johnson ME; Grassetti AV; Taroni JN; Lyons SM; Schweppe D; Gordon JK; Spiera RF; Lafyatis R; Anderson PJ; Gerber SA; Whitfield ML
    Arthritis Res Ther; 2016 Jan; 18():27. PubMed ID: 26801089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies.
    Cavazzana I; Fredi M; Taraborelli M; Quinzanini M; Tincani A; Franceschini F
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):118-21. PubMed ID: 23910615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CENP-O, a protein localized at the centromere throughout the cell cycle, is a novel target antigen in systemic sclerosis.
    Saito A; Muro Y; Sugiura K; Ikeno M; Yoda K; Tomita Y
    J Rheumatol; 2009 Apr; 36(4):781-6. PubMed ID: 19286853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis.
    Villalta D; Imbastaro T; Di Giovanni S; Lauriti C; Gabini M; Turi MC; Bizzaro N
    Autoimmun Rev; 2012 Dec; 12(2):114-20. PubMed ID: 22776784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3.
    Recke A; Regensburger AK; Weigold F; Müller A; Heidecke H; Marschner G; Hammers CM; Ludwig RJ; Riemekasten G
    Front Immunol; 2018; 9():428. PubMed ID: 29623076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests.
    Mahler M; Satoh M; Hudson M; Baron M; Chan JY; Chan EK; Wick J; Fritzler MJ;
    J Rheumatol; 2014 Jul; 41(7):1334-43. PubMed ID: 24931955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.